Elicera Therapeutics Future Growth

Future criteria checks 0/6

Elicera Therapeutics's revenue and earnings are forecast to decline at 120% and 10.1% per annum respectively while EPS is expected to decline by 9.9% per annum.

Key information

-10.1%

Earnings growth rate

-9.9%

EPS growth rate

Biotechs earnings growth	39.1%
Revenue growth rate	-120.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	06 Mar 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OM:ELIC - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-32	-34	-34	1
12/31/2025	N/A	-34	-34	-34	1
12/31/2024	N/A	-48	-60	-60	1
12/31/2023	11	-16	-15	-15	N/A
9/30/2023	12	-16	-13	-13	N/A
6/30/2023	4	-18	-4	-4	N/A
3/31/2023	2	-17	-5	-5	N/A
12/31/2022	1	-19	-9	-9	N/A
9/30/2022	1	-18	-15	-15	N/A
6/30/2022	0	-17	-24	-24	N/A
3/31/2022	0	-15	-16	-16	N/A
12/31/2021	0	-13	-14	-14	N/A
9/30/2021	0	-14	-14	-14	N/A
6/30/2021	N/A	-7	-1	-1	N/A
3/31/2021	N/A	-5	-4	-4	N/A
12/31/2020	N/A	-3	-1	-1	N/A
12/31/2019	N/A	0	0	0	N/A
12/31/2018	N/A	0	N/A	N/A	N/A
12/31/2017	N/A	0	N/A	N/A	N/A
12/31/2016	N/A	0	N/A	N/A	N/A
12/31/2015	N/A	0	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ELIC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ELIC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ELIC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ELIC is forecast to have no revenue next year.

High Growth Revenue: ELIC is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ELIC's Return on Equity is forecast to be high in 3 years time

Elicera Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

New major risk - Shareholder dilution

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

New major risk - Financial position

Elicera Therapeutics AB (publ) to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1

Elicera Therapeutics AB (Publ) Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301

Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research

Elicera Therapeutics AB (publ) Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application

New major risk - Share price stability

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

Elicera Therapeutics AB (publ) Receives Notice of Allowance for European Patent Protecting the iTANK

New major risk - Financial position

Elicera Therapeutics AB (publ) Submits Clinical Trial Application to Evaluate Its CAR T-Cell Therapy in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Continues Phase I/IIa Study with Oncolytic Virus as Planned, Following Safety Review in Cohort 3

Elicera Therapeutics AB (publ) Announces Positive Clinical Effect in Cancer Trial

Elicera Therapeutics Reports Additional Signals of Clinical Activity in Patients Treated for Neuroendocrine Tumors in the Elc-100 Study At the Oncolytic Virotherapy Summit in Boston

Elicera Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Receives EUR 2.5 Million Funding to Fully Finance Clinical Phase I/II-Trial with its Car T-Cell Therapy, ELC-301

Elicera Therapeutics Successfully Concludes Preclinical Proof-Of-Concept Studies for Oncolytic Virus ELC-201 Confirming the Proposed Mode-Of-Action

High number of new and inexperienced directors

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Enters into Agreement with Baylor College of Medicine for Contract Manufacturing of Next Generation Oncolytic Virus, ELC-201

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies